海洋放线菌NZ1203菌种鉴定及活性产物研究

Strains Identification of Marine Actinomycetes NZ1203 and Preliminary Study on Its Metabolite

目的:对海洋放线菌NZ1203进行菌种鉴定,并对其抗肿瘤代谢产物进行初步研究。方法:通过形态学观察和16S rDNA基因序列分析,鉴定菌株;用石油醚、乙酸乙酯及正丁醇对其发酵液依次进行萃取,并且通过抑菌实验和抗肿瘤实验对其发酵萃取物的活性进行初步研究。结果:通过菌株鉴定,将放线菌NZ1203归属于极暗黄链霉菌属(Streptomyces fulvissimus);乙酸乙酯提取物和正丁醇提取物具有较强的抑菌作用和良好的抗肿瘤效果,且正丁醇相优于乙酸乙酯相,石油醚相无抑菌效果。结论:海洋放线菌NZ1203为极暗黄链霉菌属,其代谢产物抑菌和抗肿瘤作用效果明显,可进一步进行分离鉴定,获得单体代谢产物,为进一步药物开发提供前期研究和物质基础。

Objective：To identify marine actinomycete NZ1203 and study its anti -tumor metabolites. Methods：The strain NZ1203 was identified according to the morphological and the 16S rDNA gene sequence analysis. Its fermentation liquor was extracted with petroleum ether, ethyl acetate and n - butyl alcohol. We tested the fermentation metabolites activity through the antibacterial experiment and anti - tumor experiment. Results ： Through strain identification, marine actinomycete NZ1203 belonged to Streptomyces fulvissimus. The ethyl acetate extract and n - butanol extract had a strong inhibitory effect and good anti - tumor effect, and n - butanol phase was superior to ethyl acetate and petroleum ether phase had no inhibitory effect. Conclusion： Marine actinomycete NZ1203NZ1203 was Streptomyces fulvissimus. Its metabolites＇ antibacterial and anti -tumor effect was significantly. It can be separated and identified in a further step and obtained monomer metabolite to provide the material basis for the further research and drug development.